Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
Education
About Us
Working with TipRanks
Follow Us
